MAP2K1 and melanoma: In view of previous research showing a synergic effect of combining MEK1/2 and PI3K inhibitors [25], we evaluated the therapeutic activity of the combinatorial approach in BRAFV600E and BRAFL577F mutated melanoma cells of brain metastatic origin.